If you know me, then you know surgical robotics is my sweet spot, so there was no way I was missing SRS2026! There's a moment at every conference where the story tells on itself. For me, that was at the pre-conference investor sessions on Wednesday. Dr. Vip Patel showed a telesurgery case performed more than 1,500 kilometers away with just 51 milliseconds of latency. This is great from a conceptual or humanitarian perspective, but what about real life? What about: Licensure?

The Part Where Enthusiasm Meets Reality and Reality Wins A pitch deck. A sales rep you hired three weeks ago. A pricing slide that got thrown together the night before a board meeting. A VP of Commercial who starts next month. A shiny new logo the leadership team spent four months arguing about. And, naturally, a LinkedIn post announcing your FDA clearance with enough fire emojis to trigger a smoke alarm. Congratulations. According to a shocking number of MedTech startups, yo

FDA clearance is not the same thing as commercial readiness. In Step 1 of the MedTech Recovery Program, we break down why clinical data, KOL strategy, study design, and early site selection often fail to translate into real U.S. adoption. Learn how successful MedTech companies build commercially relevant evidence before entering hospital systems, Value Analysis Committees, and skeptical physician workflows.

FDA clearance is not a commercial strategy. It's permission to start building one. That distinction matters more than most international MedTech founders realize until they've already arrived in the U.S. market, pitch deck in hand, expecting momentum. What they find instead: Clinical skepticism Procurement committees Reimbursement walls Hospital IT And Decision-makers with zero emotional investment in their technology. Clearance doesn't protect you from any of that. Over the